Natera, Inc. $NTRA Stock Sold by One Way Holdings LLC

One Way Holdings LLC lessened its position in Natera, Inc. (NASDAQ:NTRA) by 7.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 76,070 shares of the medical research company’s stock after selling 6,488 shares during the period. Natera comprises approximately 1.4% of One Way Holdings LLC’s holdings, making the stock its 21st biggest holding. One Way Holdings LLC’s holdings in Natera were worth $31,440,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. BlackRock Inc. bought a new position in Natera during the 2nd quarter valued at about $2,962,770,000. Bank of America Corp DE bought a new stake in Natera during the second quarter worth about $199,960,000. Legal & General Group Plc bought a new stake in Natera during the second quarter worth about $150,143,000. Bank of New York Mellon Corp acquired a new stake in shares of Natera during the second quarter worth approximately $149,278,000. Finally, Avala Global LP acquired a new stake in shares of Natera during the second quarter worth approximately $124,867,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NTRA opened at $414.30 on Monday. The stock has a market capitalization of $59.72 billion, a PE ratio of -304.63 and a beta of 1.55. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The firm has a 50-day moving average price of $377.06 and a two-hundred day moving average price of $266.44.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the firm posted ($0.74) earnings per share. The company’s revenue was up 37.7% on a year-over-year basis. On average, research analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Insider Activity at Natera

In other Natera news, CEO Steven Chapman sold 3,430 shares of the stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total value of $1,462,346.20. Following the transaction, the chief executive officer directly owned 91,232 shares in the company, valued at approximately $38,895,850.88. This trade represents a 3.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 1,162 shares of Natera stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $495,407.08. Following the completion of the sale, the insider directly owned 104,742 shares of the company’s stock, valued at $44,655,704.28. This trade represents a 1.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 45,734 shares of company stock worth $16,586,421. 5.05% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. UBS Group lifted their target price on shares of Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Citigroup increased their price target on Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. Royal Bank Of Canada raised their price target on Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Barclays lifted their price objective on Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Negative Sentiment: CFO Michael Brophy sold 1,178 shares at an average price of $426.46, generating approximately $502,370. The sale reduced his holdings by 2.37%, although it was executed under a pre-arranged Rule 10b5-1 trading plan, making it a less definitive signal about his outlook for Natera. SEC insider-trading filing
• Negative Sentiment: Additional filings reported multiple insider sales, including transactions attributed to Natera’s CEO, CFO and other insiders. The disclosed transaction values ranged from roughly $317,000 to $1.46 million, creating a broader pattern of insider selling that could weigh on sentiment. Natera insider-selling report
• Neutral Sentiment: Benzinga included Natera in its “Stock Whisper” index of companies attracting investor attention. The item provides visibility but no specific fundamental catalyst, forecast change or company announcement to directly support the shares. Benzinga Stock Whisper Index

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.